Gastric inhibitory polypeptide receptor (GIP) has been identified in the glucose-mediated secretion of insulin(Mayo et al., 2003). GIP is in the secretin/VIP receptor family which includes secretin, VIP, glucagon, GLP-1, growth hormone releasing hormone (GHRH), and PACAP (Yip et al., 1999). GIP is secreted after meal ingestion has been shown to stimulate bone formation resulting in lower occurrences of osteoporosis (Tsukiyama et al., 2006). Type 2 diabetes is a result of decreased glucose-stimulated insulin secretion which makes insulin secretion potentiators a popular target for diabetes treatments, it is thought that a defect in GIP expression and/or signaling may lead to β-cell dysfunction and type 2 diabetes (Mayo et al., 2003). Chemicon's cloned human GIP-expressing cell line is made in the Chem-9 host, which supports high levels of recombinant GIP expression on the cell surface and contains high levels of promiscuous G proteins to couple the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for antagonists of interactions between GIP and its ligands.